Literature DB >> 11858723

Expression, purification, and kinetic characterization of full-length human fibroblast activation protein.

Shaoxian Sun1, Charles F Albright, Barbara H Fish, Henry J George, Bernard H Selling, Gregory F Hollis, Richard Wynn.   

Abstract

Human fibroblast activation protein (FAP), an integral membrane serine protease, was produced in insect cells as a hexa-His-tagged protein using a recombinant baculovirus expression system. Two isoforms of FAP, glycosylated and nonglycosylated, were identified by Western blotting using an anti-His-tag antibody and separated by lectin chromatography. The glycosylated FAP was purified to near homogeneity using immobilized metal affinity chromatography and was shown to have both postprolyl dipeptidyl peptidase and postgelatinase activities. In contrast, the nonglycosylated isoform demonstrated no detectable gelatinase activity by either zymography or a fluorescence-based gelatinase activity assay. The kinetic parameters of the dipeptidyl peptidase activity for glycosylated FAP were determined using dipeptide Ala-Pro-7-amino-trifluoromethyl-coumarin as the substrate. The k(cat) is 2.0 s(-1) and k(cat)/K(m) is 1.0 x 10(4) M(-1) s(-1) at pH 8.5. The pH dependence of k(cat) reveals two ionization groups with pK(a1) of 7.0 and pK(a2) of 11.0. The pH profile of k(cat)/K(m) yields similar results with pK(a1) 6.2 and pK(a2) 11.0. The neutral pK(a1) is associated with His at the active site. The basic pK(a2) might be contributed from an ionization group that is not involved directly in catalysis, instead associated with the stability of the active site structure. Copyright 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858723     DOI: 10.1006/prep.2001.1572

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  11 in total

Review 1.  The role of fibroblast activation protein in health and malignancy.

Authors:  Allison A Fitzgerald; Louis M Weiner
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  Synthesis and activity of a potent, specific azabicyclo[3.3.0]-octane-based DPP II inhibitor.

Authors:  Olga Danilova; Bei Li; A Katrin Szardenings; Brigitte T Huber; Jonathan S Rosenblum
Journal:  Bioorg Med Chem Lett       Date:  2006-10-10       Impact factor: 2.823

3.  The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices.

Authors:  Giulio Ghersi; Qiang Zhao; Monica Salamone; Yunyun Yeh; Stanley Zucker; Wen-Tien Chen
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

4.  Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.

Authors:  Saurabh Aggarwal; W Nathaniel Brennen; Thomas P Kole; Elizabeth Schneider; Ozlem Topaloglu; Melinda Yates; Robert J Cotter; Samuel R Denmeade
Journal:  Biochemistry       Date:  2007-12-21       Impact factor: 3.162

5.  Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.

Authors:  Jiping Zhang; Matthildi Valianou; Heidi Simmons; Matthew K Robinson; Hyung-Ok Lee; Stefanie R Mullins; Wayne A Marasco; Gregory P Adams; Louis M Weiner; Jonathan D Cheng
Journal:  FASEB J       Date:  2012-10-26       Impact factor: 5.191

6.  N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding.

Authors:  Kathleen Aertgeerts; Sheng Ye; Lihong Shi; Sridhar G Prasad; Darbi Witmer; Ellen Chi; Bi-Ching Sang; Robert A Wijnands; David R Webb; Ronald V Swanson
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

7.  Fibroblast activation protein is dispensable in the anti-influenza immune response in mice.

Authors:  Sioh-Yang Tan; Sumaiya Chowdhury; Natasa Polak; Mark D Gorrell; Wolfgang Weninger
Journal:  PLoS One       Date:  2017-02-03       Impact factor: 3.240

8.  Evaluation of the radiolabeled boronic acid-based FAP inhibitor MIP-1232 for atherosclerotic plaque imaging.

Authors:  Romana Meletta; Adrienne Müller Herde; Aristeidis Chiotellis; Malsor Isa; Zoran Rancic; Nicole Borel; Simon M Ametamey; Stefanie D Krämer; Roger Schibli
Journal:  Molecules       Date:  2015-01-27       Impact factor: 4.411

Review 9.  FGF10 Signaling in Heart Development, Homeostasis, Disease and Repair.

Authors:  Fabien Hubert; Sandy M Payan; Francesca Rochais
Journal:  Front Genet       Date:  2018-11-28       Impact factor: 4.599

10.  Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy.

Authors:  W Nathaniel Brennen; Daniel L J Thorek; Wen Jiang; Timothy E Krueger; Lizamma Antony; Samuel R Denmeade; John T Isaacs
Journal:  Immunotherapy       Date:  2020-11-05       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.